These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 9352580)

  • 21. Cytochrome P450 2D6 genotype and steady state plasma levels of risperidone and 9-hydroxyrisperidone.
    Scordo MG; Spina E; Facciolà G; Avenoso A; Johansson I; Dahl ML
    Psychopharmacology (Berl); 1999 Dec; 147(3):300-5. PubMed ID: 10639689
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of various CYP2D6 genotypes on the steady-state plasma concentrations of risperidone and its active metabolite, 9-hydroxyrisperidone, in Japanese patients with schizophrenia.
    Mihara K; Kondo T; Yasui-Furukori N; Suzuki A; Ishida M; Ono S; Kubota T; Iga T; Takarada Y; de Vries R; Kaneko S
    Ther Drug Monit; 2003 Jun; 25(3):287-93. PubMed ID: 12766554
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of various factors on steady-state plasma concentrations of risperidone and 9-hydroxyrisperidone: lack of impact of MDR-1 genotypes.
    Yasui-Furukori N; Mihara K; Takahata T; Suzuki A; Nakagami T; De Vries R; Tateishi T; Kondo T; Kaneko S
    Br J Clin Pharmacol; 2004 May; 57(5):569-75. PubMed ID: 15089809
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Genotype and co-medication dependent CYP2D6 metabolic activity: effects on serum concentrations of aripiprazole, haloperidol, risperidone, paliperidone and zuclopenthixol.
    Lisbeth P; Vincent H; Kristof M; Bernard S; Manuel M; Hugo N
    Eur J Clin Pharmacol; 2016 Feb; 72(2):175-84. PubMed ID: 26514968
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of the CYP2D6*10 allele on the steady-state plasma concentrations of aripiprazole and its active metabolite, dehydroaripiprazole, in Japanese patients with schizophrenia.
    Suzuki T; Mihara K; Nakamura A; Nagai G; Kagawa S; Nemoto K; Ohta I; Arakaki H; Uno T; Kondo T
    Ther Drug Monit; 2011 Feb; 33(1):21-4. PubMed ID: 21157400
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Effect of factors on plasma haloperidol concentration/dose ratio].
    Ohara K; Shibuya H
    Nihon Shinkei Seishin Yakurigaku Zasshi; 2003 Aug; 23(4):183-6. PubMed ID: 13677914
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The drug-drug interaction effects of haloperidol on plasma carbamazepine levels.
    Iwahashi K; Miyatake R; Suwaki H; Hosokawa K; Ichikawa Y
    Clin Neuropharmacol; 1995 Jun; 18(3):233-6. PubMed ID: 8635181
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The influence of the CYP2D6 polymorphism on psychopathological and extrapyramidal symptoms in the patients on long-term antipsychotic treatment.
    Plesnicar BK; Zalar B; Breskvar K; Dolzan V
    J Psychopharmacol; 2006 Nov; 20(6):829-33. PubMed ID: 16478753
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Lack of impact of CYP1A2 genetic polymorphism (C/A polymorphism at position 734 in intron 1 and G/A polymorphism at position -2964 in the 5'-flanking region of CYP1A2) on the plasma concentration of haloperidol in smoking male Japanese with schizophrenia.
    Shimoda K; Someya T; Morita S; Hirokane G; Yokono A; Takahashi S; Okawa M
    Prog Neuropsychopharmacol Biol Psychiatry; 2002 Feb; 26(2):261-5. PubMed ID: 11817502
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prolactin concentrations during aripiprazole treatment in relation to sex, plasma drugs concentrations and genetic polymorphisms of dopamine D2 receptor and cytochrome P450 2D6 in Japanese patients with schizophrenia.
    Nagai G; Mihara K; Nakamura A; Suzuki T; Nemoto K; Kagawa S; Ohta I; Arakaki H; Kondo T
    Psychiatry Clin Neurosci; 2012 Oct; 66(6):518-24. PubMed ID: 23066770
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Maintenance therapy with zuclopenthixol decanoate: associations between plasma concentrations, neurological side effects and CYP2D6 genotype.
    Jaanson P; Marandi T; Kiivet RA; Vasar V; Vään S; Svensson JO; Dahl ML
    Psychopharmacology (Berl); 2002 Jun; 162(1):67-73. PubMed ID: 12107620
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Risperidone plasma levels, clinical response and side-effects.
    Riedel M; Schwarz MJ; Strassnig M; Spellmann I; Müller-Arends A; Weber K; Zach J; Müller N; Möller HJ
    Eur Arch Psychiatry Clin Neurosci; 2005 Aug; 255(4):261-8. PubMed ID: 15565299
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Risperidone metabolism in relation to CYP2D6*10 allele in Korean schizophrenic patients.
    Roh HK; Kim CE; Chung WG; Park CS; Svensson JO; Bertilsson L
    Eur J Clin Pharmacol; 2001 Nov; 57(9):671-5. PubMed ID: 11791898
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Thioridazine steady-state plasma concentrations are influenced by tobacco smoking and CYP2D6, but not by the CYP2C9 genotype.
    Berecz R; de la Rubia A; Dorado P; Fernández-Salguero P; Dahl ML; LLerena A
    Eur J Clin Pharmacol; 2003 May; 59(1):45-50. PubMed ID: 12682803
    [TBL] [Abstract][Full Text] [Related]  

  • 35. CYP2D6 polymorphisms and atypical antipsychotic weight gain.
    Ellingrod VL; Miller D; Schultz SK; Wehring H; Arndt S
    Psychiatr Genet; 2002 Mar; 12(1):55-8. PubMed ID: 11901361
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Histamine H1-receptor antagonists, promethazine and homochlorcyclizine, increase the steady-state plasma concentrations of haloperidol and reduced haloperidol.
    Suzuki A; Yasui-Furukori N; Mihara K; Kondo T; Furukori H; Inoue Y; Kaneko S; Otani K
    Ther Drug Monit; 2003 Apr; 25(2):192-6. PubMed ID: 12657913
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Correlation between steady-state plasma concentrations (Css) of bromperidol and haloperidol.
    Yasui N; Otani K; Kondo T; Suzuki A; Furukori H; Kaneko S; Inoue Y
    Prog Neuropsychopharmacol Biol Psychiatry; 1998 Apr; 22(3):485-92. PubMed ID: 9612845
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects of smoking and cytochrome P450 2D6*10 allele on the plasma haloperidol concentration/dose ratio.
    Ohara K; Tanabu S; Yoshida K; Ishibashi K; Ikemoto K; Shibuya H
    Prog Neuropsychopharmacol Biol Psychiatry; 2003 Sep; 27(6):945-9. PubMed ID: 14499311
    [TBL] [Abstract][Full Text] [Related]  

  • 39. CYP2D6 genotype predicts antipsychotic side effects in schizophrenia inpatients: a retrospective matched case-control study.
    Kobylecki CJ; Jakobsen KD; Hansen T; Jakobsen IV; Rasmussen HB; Werge T
    Neuropsychobiology; 2009; 59(4):222-6. PubMed ID: 19521114
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of age and the CYP2D6*10 allele on the plasma haloperidol concentration/dose ratio.
    Ohara K; Tanabu S; Ishibashi K; Ikemoto K; Yoshida K; Shibuya H
    Prog Neuropsychopharmacol Biol Psychiatry; 2003 May; 27(3):347-50. PubMed ID: 12691769
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.